-
What is the contribution of nuclear medicine to personalized medicine?
Nuclear medicine visualizes both the anatomy of the body and its functions, contributing to personalized treatment. In cancer patients, we can visualize how much energy tumor cells require. As tumor cells progress, they need a lot of energy. Using FTG, a radio-labeled glucose-like sugar, we determine energy needs. A PET-CT scan with this glucose can be performed a few weeks after treatment to monitor if the cancer is still growing. If it has stopped, it will not absorb the glucose, which will indicate whether the applied therapy is effective.
-
Nuclear medicine aids in cancer staging by visualizing how cells and tissues function within the body. This is often achieved through the use of radiopharmaceuticals, which are substances containing small amounts of radioactive materials. These radiopharmaceuticals are administered to the patient, typically injected or swallowed. Here's how nuclear medicine contributes to cancer staging: * **Detecting Cancer Spread (Metastasis):** Cancer can spread from its primary site to other parts of the body. Nuclear medicine imaging, such as bone scans or PET scans, can detect these metastases at a cellular level, sometimes before they are visible on other imaging modalities. For example, a bone scan can identify if cancer has spread to the bones, which is crucial for determining the stage. * **Assessing Tumor Activity:** Radiopharmaceuticals can target specific biological processes within cancer cells, such as increased metabolism or the presence of certain receptors. This allows doctors to assess how aggressive a tumor is and if it is actively growing or spreading. For instance, FDG-PET scans use a radioactive glucose analog; cancer cells often consume more glucose, making them light up on the scan and indicating high metabolic activity. * **Identifying Lymph Node Involvement:** Lymph nodes are a common pathway for cancer to spread. Certain nuclear medicine techniques can help determine if cancer cells have invaded nearby lymph nodes, which is a critical factor in staging. Sentinel lymph node biopsies, a nuclear medicine procedure, inject a radioactive tracer near a tumor to identify the first lymph node(s) that drain the area. If these "sentinel" nodes are free of cancer, it's less likely the cancer has spread further. * **Evaluating Treatment Effectiveness:** While not directly part of the initial staging, nuclear medicine can also be used to monitor treatment response. If a tumor's activity decreases on a follow-up nuclear medicine scan after treatment, it suggests the treatment is working, which can indirectly inform subsequent management decisions. * **Guiding Biopsies:** In some cases, nuclear medicine techniques can help pinpoint suspicious areas for biopsy, ensuring that the sample taken is representative of the potentially cancerous tissue. In summary, nuclear medicine provides functional information about tumors and their potential spread, complementing anatomical imaging like CT or MRI. This functional insight is vital for accurate cancer staging, which in turn guides the selection of the most appropriate treatment plan and helps predict prognosis.
In nuclear medicine, we use whole-body imaging techniques that significantly aid in cancer patient staging. When performing PET-CT with FDG, in addition to determining the amount of glucose taken up by tumor cells, we can also obtain images of inflammatory cells.
-
What is the theranostic strategy?
Theragnostics is an innovative method in the treatment of prostate cancer that uses radiolabeled PSMA. The PSMA in question is a surface antigen of prostate cancer cells and metastatic prostate cancer cells. We label it with diagnostic radioligands, such as Gallium 68 or F18. We use similar compounds when there are progressing metastases.
-
How does lutetium-177 therapy work for prostate cancer?
Lutetium-177 PSMA is an innovative drug for the treatment of prostate cancer. Most patients in advanced stages suffer from severe pain due to bone metastases, leading to a reduced quality of life due to immobility and fatigue. The administration of Lutetium-177 provides both symptomatic relief and prolonged survival without cancer progression.
